阿帕替尼联合白蛋白结合型紫杉醇治疗食管癌术后远处转移的临床研究

中华养生保健 ›› 2023, Vol. 41 ›› Issue (15): 16-19.

阿帕替尼联合白蛋白结合型紫杉醇治疗食管癌术后远处转移的临床研究

李梁¹, 亓迪¹, 李玉¹, 袁磊¹, 王娥¹, 朱俊迪¹, 耿晓萌², 李文文¹, 任伟^3,*

1.泰安市肿瘤防治院放疗科,山东泰安,271000;
2.泰安市中心医院儿内科,山东泰安,271000;
3.解放军第九〇六医院疾病预防控制科,浙江宁波,315000

出版日期:2023-08-01 发布日期:2023-08-03
通讯作者: ^* 任伟,E-mail：3078119445@qq.com。
作者简介:李梁（1980—）,男,汉族,籍贯：山东省泰安市,硕士研究生,主治医师,研究方向：肿瘤放化疗。

Clinical Study of Apatinib Combined with Albumin-bound Paclitaxel in the Treatment of Distant Metastasis after Surgery for Esophageal Cancer

LI Liang¹, QI Di¹, LI Yu¹, YUAN Lei¹, WANG E¹, ZHU Jun-di¹, GENG Xiao-meng², LI Wen-wen¹, REN Wei^3,*

1. Department of Radiotherapy, Tai'an Cancer Prevention and Treatment Hospital, Tai'an Shandong 271000,China;
2. Department of Pediatrics, Tai'an Central Hospital, Tai'an Shandong 271000,China;
3. Department of Disease Control and Prevention, 906th Hospital of PLA, Ningbo Zhejiang 315000,China

Online:2023-08-01 Published:2023-08-03

摘要/Abstract

摘要： 目的探讨阿帕替尼联合白蛋白结合型紫杉醇治疗食管癌术后远处转移患者的疗效及不良反应。方法回顾性分析泰安市肿瘤防治院2019年3月—2022年1月收治的70例食管癌术后远处转移患者,根据治疗方案不同分为治疗组（注射用紫杉醇白蛋白结合型联合阿帕替尼治疗）35例,对照组（单用注射用紫杉醇白蛋白结合型化疗）35例,观察两组的近期疗效、无病进展期以及不良反应。结果治疗组客观缓解率（ORR）、疾病控制率（DCR）高于对照组,差异有统计学意义（P<0.05）;治疗组中位无进展生存期（PFS）较对照组长,差异有统计学意义（P<0.05）;治疗过程中两组均出现白细胞下降、血小板下降、肝功异常、胃肠道反应等不良反应,组间比较差异无统计学意义（P>0.05）;治疗组在口服阿帕替尼期间发生高血压、蛋白尿、手足综合征症状均能耐受,对症处理后均能缓解,两组比较差异无统计学意义（P>0.05）。结论阿帕替尼联合白蛋白结合型紫杉醇治疗食管癌术后远处转移的患者,局部控制率好,无病进展期延长,不良反应少。

关键词: 食管癌, 阿帕替尼, 紫杉醇

Abstract: Objective To investigate the efficacy and adverse effects of apatinib combined with albumin-bound paclitaxel in the treatment of patients with distant metastases after esophageal cancer. Methods A retrospective analysis was performed on 70 patients with distant metastasis after esophageal cancer admitted to Tai'an Cancer Hospital from March 2019 to January 2022, according to the treatment plan, 35 cases were divided into treatment group (paclitaxel albumin-binding combination with apatinib for injection) and 35 cases in the control group (paclitaxel albumin-binding chemotherapy for single-agent injection), and the short-term efficacy, disease-free progression, and adverse reactions of the two groups were observed. Results The difference was statistically significant compared with the objective response rate (ORR) and the disease control rate (DCR) between the treatment group and the control group (P<0.05). There were statistical differences between the median PFS of the treatment group and the control group (P<0.05). There were no significant differences in white blood cell decrease, platelet decrease, abnormal liver function, and gastrointestinal reactions during treatment (P>0.05), The symptoms of hypertension, proteinuria, and hand-foot syndrome in the treatment group were tolerated during oral apatinib, and alleviated after symptomatic treatment, and there was no significant difference between the two groups (P>0.05). Conclusion Apatinib combined with albumin-bound paclitaxel in patients with distant metastasis after esophageal cancer surgery has good local control rate, prolonged disease-free progression, and less adverse reactions.

Key words: esophageal cancer, apatinib, paclitaxel

中图分类号:

R730.5

李梁, 亓迪, 李玉, 袁磊, 王娥, 朱俊迪, 耿晓萌, 李文文, 任伟. 阿帕替尼联合白蛋白结合型紫杉醇治疗食管癌术后远处转移的临床研究[J]. 中华养生保健, 2023, 41(15): 16-19.

LI Liang, QI Di, LI Yu, YUAN Lei, WANG E, ZHU Jun-di, GENG Xiao-meng, LI Wen-wen, REN Wei. Clinical Study of Apatinib Combined with Albumin-bound Paclitaxel in the Treatment of Distant Metastasis after Surgery for Esophageal Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(15): 16-19.

参考文献

[1] JI Y, DU X, ZHU W, et al.Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial[J]. JAMA Oncol,2021,7(10):1459-1466.
[2] 李玉,耿晓萌,李文文,等.低剂量多西他赛周疗同步放疗治疗局部晚期食管癌的疗效与安全性分析[J].现代肿瘤医学,2021,29(5):787-789.
[3] XU W W, LI B, CHEUNG A.The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer[J]. Gastrointestinal Cancer: Targets and Therapy,2015,5:79-88.
[4] WATANABE S, OGINO I, KUNISAKI C, et al.Sequential chemotherapy after definitive radiotherapy in markedly elderly patients with advanced esophageal cancer[J]. Indian J Cancer,2022,59(2):244-250.
[5] SCOTT L J.Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers[J]. Drugs,2018,78(7):759.
[6] 周志国,甄婵军,梁军利,等.食管癌AJCC/UICC第6、7版TNM分期分段方法在放疗患者中的比较[J].肿瘤防治研究,2015,42(8):772-776.
[7] 毛友生,高树庚,王群,等.中国食管癌临床流行特征及外科治疗概况大数据分析[J].中华肿瘤杂志,2020,42(3):228-233.
[8] 亓磊,田辉,李林,等.微创食管癌切除术后淋巴结转移规律及预后分析[J].中华腔镜外科杂志(电子版),2018,11(2):98-102.
[9] 颜芳,应明真,陈龙佩,等.白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察[J].中国癌症杂志,2020,30(8):632-635.
[10] JING S W, QIN J J, LIU Q, et al.Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis[J]. Future Oncol,2019,15(20):2413-2422.
[11] MA D Y, TAN B X, LIU M, et al.Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study[J]. Radiat Oncol,2014,9:28.
[12] 王振华,师国珍,武莉萍,等.低剂量紫杉醇联合调强放疗治疗食管癌放疗后复发疗效观察[J].中华实用诊断与治疗杂志,2015,29(6):617-619.
[13] YUAN Y, ZHANG Y, SHI L, et al.Clinical Research on Albumin-Bound Paclitaxel-Based Chemotherapy for Advanced Esophageal Cancer[J]. Asian Pac J Cancer Prev,2015,16(12):4993-4996.
[14] ZHANG W, LI Y, XUE L, et al.Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study[J]. Cancer Manag Res,2021,13:2163-2170.
[15] YANWEI L, FENG H, REN P, et al.Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study[J]. Oncologist,2020,25(10):e1464-e1472.
[16] LI J, JIA Y, GAO Y, et al.Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer[J]. Onco Targets Ther,2019,12:2577-2583.
[17] LIANG L J, WEN Y X, XIA Y Y, et al.Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report[J]. Onco Targets Ther,2018,11:5821-5826.
[18] CHI D, CHEN B, GUO S, et al.Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy[J]. Aging (Albany NY),2021,13(6):8408-8420.
[19] LIU G, E M, WANG C, et al. Concurrent apatinib and local radiation therapy for advanced esophageal adenocarcinoma[J]. J Biol Regul Homeost Agents,2019,33(4):1177-1182.
[20] 刘娟,徐舟,卢宏霞,等.阿帕替尼联合白蛋白紫杉醇治疗晚期食管癌效果及安全性[J].中国药物与临床,2021,21(8):1375-1377.
[21] 周鹏程,张月,潘媛媛,等.阿帕替尼联合TP化疗方案治疗晚期食管癌的临床疗效及安全性分析[J].医药论坛杂志,2019,40(11):50-54,58.
[22] 李琳,蔡晓军.阿帕替尼联合紫杉醇二线治疗晚期食管癌的临床研究[J].实用肿瘤杂志,2020,35(3): 241-244.